The following articles (labelled with PubMed ID or TBD) are for your review
||Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase.
||Takeda California, 10410 Science Center Drive, San Diego, California 92121, United States.
||Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
||Massachusetts Institute of Technology
||Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-ß type I receptor kinase as cancer immunotherapeutic/antifibrotic agent.
||Ewha Womans University
||Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe.
||Vanderbilt University Medical Center
||Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.
||A quantitative analysis of kinase inhibitor selectivity.
||Comprehensive analysis of kinase inhibitor selectivity.
||AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
||In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors.